Pfizer, BMS report Phase II clotting trial success

More on the clotting drug race: Bristol-Myers Squibb and Pfizer announced that their oral anti-clotting therapy--apixaban--demonstrated comparability to the current standard of care that relies on an injectable combined with a drug that includes warfarin. The experimental pill hit its endpoints in a mid-stage study for the rates of blood clots and dangerous bleeding. The researchers say that a comparable therapy would allow patients to bypass a standard approach that includes harsh side effects and regular injections. Apixaban doesn't require close monitoring or dose adjustments.

- read the report from CNNMoney

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.